Department of Pathology
Peng Wang is a surgical, clinical, and molecular pathologist. As a molecular genetic pathology fellow at The University of Texas MD Anderson Cancer Center, he investigated the clinical utility of next-generation sequencing liquid biopsy assays in choosing targeted therapy for lung and colorectal carcinoma; evaluated the concordance between liquid and tissue biopsies; and correlated liquid biopsy assay results with tumor grades/stages and radiological findings. He also developed and validated optimized microsatellite markers for endometrial cancer.
His research findings have been published in Oncotarget, Frontiers in Endocrinology (Lausanne), International Journal of Ophthalmic Pathology, Histopathology, Journal of Thoracic Oncology, and Journal of Biological Chemistry.
Wang holds a bachelor of medicine degree from China Medical University in Shenyang, and a doctorate in cell and molecular biology from Catholic University of America. He then completed a postdoctoral fellowship at the National Institute of Diabetes and Digestive and Kidney Diseases. He was also an anatomic pathology/clinical pathology resident at Medstar Georgetown University Hospital and a selective service pathology fellow at Hartford Hospital in Connecticut. Most recently, he was a molecular and surgical pathologist at the Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research.